Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?

The Lancet Infectious Diseases

Volumn 15, Issue 6, 2015, Pages 738-745

  Lanini, Simone ^a   Zumla, Alimuddin ^b,c   Ioannidis, John P A ^d   Di Caro, Antonino ^a   Krishna, Sanjeev ^e   Gostin, Lawrence ^f   Girardi, Enrico ^a   Pletschette, Michel ^g   Strada, Gino ^h   Baritussio, Aldo ⁱ   Portella, Gina ^h   Apolone, Giovanni ^j   Cavuto, Silvio ^j   Satolli, Roberto ^k   Kremsner, Peter ^l,m   Vairo, Francesco ^a   Ippolito, Giuseppe ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^g UNIVERSITY OF ZURICH   (Switzerland)

^h Istituto OIKOS   (Italy)

ⁱ UNIVERSITY OF PADOVA   (Italy)

^j S MARIA NUOVA HOSPITAL   (Italy)

^k Science and Health communication   (Italy)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^m German Center for Infection Research   (Gabon)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR;

AFRICA; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; EQUIPOISE; EXPERIMENTAL THERAPY; HEALTH CARE QUALITY; HUMAN; MORTALITY; NOTE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERE ACUTE RESPIRATORY SYNDROME; SIMULATION; STUDY DESIGN; VIRUS LOAD; ETHICS; HEMORRHAGIC FEVER, EBOLA; MEDICAL RESEARCH; PROCEDURES;

AFRICA, WESTERN; BIOMEDICAL RESEARCH; DISEASE OUTBREAKS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84929510507     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70106-4     Document Type: Note

References (40)

1. Hooper C, Krishna S This must be the year we beat Ebola in West Africa (accessed March 31, 2015). https://theconversation.com/this-must-be-the-year-we-beat-ebola-in-west-africa-35832.
2. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med 2014, 371:1481-1495. WHO Ebola Response Team.
3. Brouqui P, Ippolito G Ebola and travel-management of imported cases. Travel Med Infect Dis 2014, 12:561-562.
4. Ebola Situation Report WHO, (accessed March 30, 2015). http://apps.who.int/ebola/current-situation/ebola-situation-report-25-march-2015.
5. Ethical considerations for use of unregistered interventions for Ebola viral disease: report of an advisory panel to WHO Aug 11, 2014, WHO, World Health Organization Press, Geneva, (accessed Dec 1, 2014). http://www.who.int/csr/resources/publications/ebola/ethical-considerations/en/.
6. Adebamowo C, Bah-Sow O, Binka F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014, 384:1423-1424.
7. Cox E, Borio L, Temple R Evaluating Ebola therapies-the case for RCTs. N Engl J Med 2014, 371:2350-2351.
8. Djulbegovic B, Hozo I, Ioannidis JP Improving the drug development process: more not less randomized trials. JAMA 2014, 311:355-356.
9. Gehring G, Rohrmann K, Atenchong N, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother 2014, 69:2123-2131.
10. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
11. Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014, 371:2402-2409. the Emory Serious Communicable Diseases Unit.
12. Bishop BM Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 2015, 49:196-206.
13. Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014, 371:2394-2401.
14. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999, 179(suppl 1):S18-S23. the International Scientific and Technical Committee.
15. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease: empirical treatment during outbreaks WHO, (accessed March 31, 2015). http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/.
16. Yu ZM, Liu ZH, Chen J, Zeng Q Anti-inflammatory effect of Qingwen Baidu Decoction in sepsis rats. Chin J Integr Med 2014, 20:934-943.
17. Xu Q, Liu J, Guo X, et al. Xuebijing injection reduces organ injuries and improves survival by attenuating inflammatory responses and endothelial injury in heatstroke mice. BMC Complement Altern Med 2015, 15:4.
18. Sissoko D, Anglaret X, Malvy D, et al. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Conference on Retroviruses and Opportunistic Infections: Seattle, WA. February 23-26, 2015. 103-ALB.
19. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014, 105:17-21.
20. Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 2014, published online Dec 18. http://dx.doi.org/10.1016/S0140-6736(14)62384-9.
21. Parra JM, Salmerón OJ, Velasco M The first case of Ebola virus disease acquired outside Africa. N Engl J Med 2014, 371:2439-2440.
22. Shaw LW, Chalmers TC Ethics in cooperative clinical trials. Ann N Y Acad Sci 1970, 169:487-495.
23. Byar DP, Simon RM, Friedewald WT, et al. Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med 1976, 295:74-80.
24. Spodick DH The randomized controlled clinical trial. Scientific and ethical bases. Am J Med 1982, 73:420-425.
25. Royall RM, Bartlett RH, Cornell RG, et al. Ethics and statistics in randomized clinical trials. Stat Sci 1991, 6:52-88.
26. Colli A, Pagliaro L, Duca P The ethical problem of randomization. Intern Emerg Med 2014, 9:799-804.
27. Borchert M, Mutyaba I, Van Kerkhove MD, et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned. BMC Infect Dis 2011, 11:357.
28. Ebola virus disease WHO, (accessed Dec 1, 2014). http://www.who.int/mediacentre/factsheets/fs103/en.
29. Lamontagne F, Clément C, Fletcher T, Jacob ST, Fischer WA, Fowler RA Doing today's work superbly well-treating Ebola with current tools. N Engl J Med 2014, 371:1565-1566.
30. Meslin EM, Blasimme A, Cambon-Thomsen A Mapping the translational science policy 'valley of death'. Clin Transl Med 2013, 2:14.
31. Emanuel EJ, Wendler D, Grady C What makes clinical research ethical?. JAMA 2000, 283:2701-2711.
32. Yong E Trials at the ready: preparing for the next pandemic. BMJ 2012, 344:e2982.
33. Shaw D Randomisation is essential in Ebola drug trials. Lancet 2014, 384:1667.
34. Ethical issues related to study design for trials on therapeutics for Ebola Virus Disease Oct 21, 2014, WHO, World Health Organization Press, Geneva, (accessed March 31, 2015). http://www.who.int/csr/resources/publications/ebola/ethical-evd-therapeutics/en/.
35. Chow SC, Chang M Adaptive design methods in clinical trials- a review. Orphanet J Rare Dis 2008, 3:11.
36. Joffe S Evaluating novel therapies during the Ebola epidemic. JAMA 2014, 312:1299-1300.
37. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design European Medicines Agency Committee for Medicinal Products for Human Use, (accessed March 31, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf.
38. Federal Drug Administration Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics Center for Drug Evaluation and Research Rockville US Food and Drug Administration, (accessed March 31, 2015). http://www.fda.gov/downloads/Drugs/Guidances/ucm201790.pdf.
39. van der Graaf R, Roes KC, van Delden JJ Adaptive trials in clinical research: scientific and ethical issues to consider. JAMA 2012, 307:2379-2380.
40. Ippolito G, Feldmann H, Lanini S, et al. Viral hemorrhagic fevers: advancing the level of treatment. BMC Med 2012, 10:31.